Chlorpheniramine Maleate Market By Dosage Form (Tablets, Syrup, Eye Drops), By Application (Allergy, Hay Fever (Allergic Rhinitis), Common Cold, Watery Eyes, Itchy Throat/Skin, Anaphylactic Shock, Urticaria), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032
The chlorpheniramine maleate market size was valued at $468.6 million in 2022, and is projected to reach $751.4 million by 2032, growing at a CAGR of 4.9% from 2023 to 2032.
Chlorpheniramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold. These symptoms include rashes, watery eyes, itchy eyes/nose/throat/skin, cough, runny nose, and sneezing. This medication works by blocking a certain natural substance (histamine) that the body makes during an allergic reaction. By blocking another natural substance made by the body (acetylcholine), it helps dry up some body fluids to relieve symptoms such as watery eyes and runny nose.
The key factor that drives the growth of the chlorpheniramine maleate market is the rise in prevalence of allergies and related respiratory conditions such as allergic rhinitis, and hives. For instance, according to report published by Asthma & Allergy Foundation of America in 2021, approximately 81 million people in the U.S. were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 26% (67 million) of adults and 19% (14 million) of children. Furthermore, advances in pharmaceutical technology and drug delivery systems have resulted in the development of new formulations of chlorpheniramine maleate, such as extended-release tablets or liquid formulations, which offer improved efficacy, convenience, and patient compliance that are expected to drive the growth of the market during the forecast period.
However, changes in consumer preferences, such as a shift towards natural remedies, holistic approaches, or preferences for other types of medications, and potential adverse effects of chlorpheniramine maleate, such as drowsiness, dry mouth, blurred vision, and urinary retention hamper market growth. Conversely, a surge in R&D activities for the development of novel therapies with fewer side effects and greater efficacy is expected to provide lucrative opportunities for the growth of the market during the forecast period.
The chlorpheniramine maleate market is segmented into dosage form, application, end user, and region. By dosage form, the market is classified into tablets, syrup, and eye drops. On the basis of application, it is fragmented into allergy, hay fever (allergic rhinitis), common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria. By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America garnered the maximum share of the chlorpheniramine maleate market in 2022 and is anticipated to remain dominant during the forecast period. This is attributed to an increase in prevalence of allergic conditions, a growth in geriatric population as adults may have a higher risk of developing allergies and high healthcare expenditure on drugs used to treat allergic conditions such as hay fever, the common cold, anaphylactic shock, and others. Furthermore, a surge in awareness among the population about the symptoms and management of allergies and advancements in healthcare infrastructure are expected to fuel the market growth.
Asia-Pacific is expected to register the fastest CAGR during the forecast period owing to an increase in incidence of allergic conditions and a surge in population and urbanization. Furthermore, growth in healthcare infrastructure and surge in R&D activities by key market players for the development of new drugs to treat allergic disorders such as allergic rhinitis, urticaria, and hay fever boost the growth of the market.
The key players that operate in the chlorpheniramine maleate market are Alkeem Laboratories Ltd., Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novalab Healthcare Pvt. Ltd., Capellon Pharmaceuticals, Sun Pharmaceutical Industries Limited, Viatris Inc., and Zydus Lifesciences Limited.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chlorpheniramine maleate market analysis from 2022 to 2032 to identify the prevailing chlorpheniramine maleate market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the chlorpheniramine maleate market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global chlorpheniramine maleate market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Dosage Form
Syrup
Eye Drops
Tablets
By Application
Allergy
Hay Fever (Allergic Rhinitis)
Common Cold
Watery Eyes
Itchy Throat/Skin
Anaphylactic Shock
Urticaria
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Alkem Laboratories Ltd.
Bayer AG
Capellon Pharmaceuticals
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novalab Healthcare Pvt. Ltd.
Sun Pharmaceutical Industries Limited
Viatris Inc.
Zydus Lifesciences Limited
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in urbanization and change in lifestyles
- 3.4.1.2. Increase in the prevalence of allergic conditions
- 3.4.1.3. Surge in technological advancement
- 3.4.2. Restraints
- 3.4.2.1. Potential side effects of chlorpheniramine maleate
- 3.4.2.2. Increase in shift towards alternative medicines
- 3.4.3. Opportunities
- 3.4.3.1. High growth potential in developing economies
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Tablets
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Syrup
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Eye Drops
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- CHAPTER 5: CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Allergy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Hay Fever (Allergic Rhinitis)
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Common Cold
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Watery Eyes
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- 5.6. Itchy Throat/Skin
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
- 5.7. Anaphylactic Shock
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country
- 5.8. Urticaria
- 5.8.1. Key market trends, growth factors and opportunities
- 5.8.2. Market size and forecast, by region
- 5.8.3. Market share analysis by country
- CHAPTER 6: CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: CHLORPHENIRAMINE MALEATE MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Dosage Form
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Dosage Form
- 7.2.5.1.3. Market size and forecast, by Application
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Dosage Form
- 7.2.5.2.3. Market size and forecast, by Application
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Dosage Form
- 7.2.5.3.3. Market size and forecast, by Application
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Dosage Form
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Dosage Form
- 7.3.5.1.3. Market size and forecast, by Application
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Dosage Form
- 7.3.5.2.3. Market size and forecast, by Application
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Dosage Form
- 7.3.5.3.3. Market size and forecast, by Application
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Dosage Form
- 7.3.5.4.3. Market size and forecast, by Application
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Dosage Form
- 7.3.5.5.3. Market size and forecast, by Application
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Dosage Form
- 7.3.5.6.3. Market size and forecast, by Application
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Dosage Form
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Dosage Form
- 7.4.5.1.3. Market size and forecast, by Application
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Dosage Form
- 7.4.5.2.3. Market size and forecast, by Application
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. Australia
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Dosage Form
- 7.4.5.3.3. Market size and forecast, by Application
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. India
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Dosage Form
- 7.4.5.4.3. Market size and forecast, by Application
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Dosage Form
- 7.4.5.5.3. Market size and forecast, by Application
- 7.4.5.5.4. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Dosage Form
- 7.4.5.6.3. Market size and forecast, by Application
- 7.4.5.6.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Dosage Form
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Dosage Form
- 7.5.5.1.3. Market size and forecast, by Application
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Dosage Form
- 7.5.5.2.3. Market size and forecast, by Application
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Dosage Form
- 7.5.5.3.3. Market size and forecast, by Application
- 7.5.5.3.4. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Dosage Form
- 7.5.5.4.3. Market size and forecast, by Application
- 7.5.5.4.4. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. GlaxoSmithKline plc
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Bayer AG
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Merck & Co., Inc.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Johnson & Johnson
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.5. Alkem Laboratories Ltd.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Viatris Inc.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Zydus Lifesciences Limited
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Sun Pharmaceutical Industries Limited
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Novalab Healthcare Pvt. Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.10. Capellon Pharmaceuticals
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- LIST OF TABLES
- TABLE 01. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 02. CHLORPHENIRAMINE MALEATE MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. CHLORPHENIRAMINE MALEATE MARKET FOR SYRUP, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. CHLORPHENIRAMINE MALEATE MARKET FOR EYE DROPS, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 06. CHLORPHENIRAMINE MALEATE MARKET FOR ALLERGY, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. CHLORPHENIRAMINE MALEATE MARKET FOR HAY FEVER (ALLERGIC RHINITIS), BY REGION, 2022-2032 ($MILLION)
- TABLE 08. CHLORPHENIRAMINE MALEATE MARKET FOR COMMON COLD, BY REGION, 2022-2032 ($MILLION)
- TABLE 09. CHLORPHENIRAMINE MALEATE MARKET FOR WATERY EYES, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. CHLORPHENIRAMINE MALEATE MARKET FOR ITCHY THROAT/SKIN, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. CHLORPHENIRAMINE MALEATE MARKET FOR ANAPHYLACTIC SHOCK, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. CHLORPHENIRAMINE MALEATE MARKET FOR URTICARIA, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 14. CHLORPHENIRAMINE MALEATE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 15. CHLORPHENIRAMINE MALEATE MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 16. CHLORPHENIRAMINE MALEATE MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 17. CHLORPHENIRAMINE MALEATE MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 18. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 19. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 20. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 21. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 22. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 23. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 24. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 25. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 26. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 27. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 28. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 29. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 30. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 31. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 32. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 33. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 34. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 35. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 36. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 37. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 38. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 39. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 40. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 41. UK CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 42. UK CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 43. UK CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 44. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 45. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 46. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 47. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 48. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 49. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 50. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 51. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 52. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 53. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 54. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 55. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 56. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 57. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 58. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 59. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 60. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 61. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 62. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 63. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 64. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 65. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 66. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 67. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 68. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 69. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 70. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 71. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 72. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 73. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 74. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 75. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 76. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 77. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 78. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 79. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 80. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 81. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 82. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 83. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 84. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 85. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 86. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 87. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 88. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
- TABLE 89. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 90. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 91. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
- TABLE 92. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
- TABLE 94. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 95. BAYER AG: KEY EXECUTIVES
- TABLE 96. BAYER AG: COMPANY SNAPSHOT
- TABLE 97. BAYER AG: PRODUCT SEGMENTS
- TABLE 98. BAYER AG: PRODUCT PORTFOLIO
- TABLE 99. MERCK & CO., INC.: KEY EXECUTIVES
- TABLE 100. MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 101. MERCK & CO., INC.: PRODUCT SEGMENTS
- TABLE 102. MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 103. JOHNSON & JOHNSON: KEY EXECUTIVES
- TABLE 104. JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 105. JOHNSON & JOHNSON: PRODUCT SEGMENTS
- TABLE 106. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 107. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
- TABLE 108. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
- TABLE 109. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
- TABLE 110. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
- TABLE 111. VIATRIS INC.: KEY EXECUTIVES
- TABLE 112. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 113. VIATRIS INC.: PRODUCT SEGMENTS
- TABLE 114. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 115. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
- TABLE 116. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
- TABLE 117. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
- TABLE 118. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
- TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 121. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
- TABLE 122. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- TABLE 123. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
- TABLE 124. NOVALAB HEALTHCARE PVT. LTD.: KEY EXECUTIVES
- TABLE 125. NOVALAB HEALTHCARE PVT. LTD.: COMPANY SNAPSHOT
- TABLE 126. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT SEGMENTS
- TABLE 127. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT PORTFOLIO
- TABLE 128. CAPELLON PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 129. CAPELLON PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 130. CAPELLON PHARMACEUTICALS: PRODUCT SEGMENTS
- TABLE 131. CAPELLON PHARMACEUTICALS: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. CHLORPHENIRAMINE MALEATE MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF CHLORPHENIRAMINE MALEATE MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN CHLORPHENIRAMINE MALEATE MARKET (2023-2032)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCHLORPHENIRAMINE MALEATE MARKET
- FIGURE 10. CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR TABLETS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR SYRUP, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR EYE DROPS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ALLERGY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR HAY FEVER (ALLERGIC RHINITIS), BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR COMMON COLD, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR WATERY EYES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ITCHY THROAT/SKIN, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ANAPHYLACTIC SHOCK, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR URTICARIA, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
- FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 25. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 26. CHLORPHENIRAMINE MALEATE MARKET BY REGION, 2022
- FIGURE 27. U.S. CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 28. CANADA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 29. MEXICO CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 30. GERMANY CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 31. FRANCE CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 32. UK CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 33. ITALY CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 34. SPAIN CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 35. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 36. JAPAN CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 37. CHINA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 38. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 39. INDIA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 40. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 41. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 42. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 43. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 44. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 45. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50. COMPETITIVE DASHBOARD
- FIGURE 51. COMPETITIVE HEATMAP: CHLORPHENIRAMINE MALEATE MARKET
- FIGURE 52. TOP PLAYER POSITIONING, 2022
- FIGURE 53. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
- FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 55. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 56. BAYER AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 57. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 58. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 59. MERCK & CO., INC.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 60. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 61. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 62. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
- FIGURE 63. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 64. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 65. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 66. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 67. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 68. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 69. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 70. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 71. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 72. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
- FIGURE 73. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook